GCN1 activator of EIF2AK4Genealiases: GCN1L · GCN1L1 · PRIC295
Q-omics provides the consensus-scored GCN1 profile across patient tissues and cancer cell-line models. GCN1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GCN1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, GCN1 protein abundance shows 32,904 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, COAD, and LSCC as cancer lineages where GCN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCN1 survival associations across molecular data types. GCN1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCN1 RNA expression–survival associations across cancer types. High GCN1 expression shows unfavorable associations in MESO, LIHC, ACC and KICH, but favorable associations in SCLC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for GCN1 RNA expression.
This table summarizes GCN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GCN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCN1 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, LIHC, BLCA and STAD. The COAD box plot shows higher GCN1 RNA expression in tumor versus normal tissue (log2 FC = +0.847, t-test p < 0.001).
This table shows molecular features associated with GCN1 in patient tissues and cancer cell lines. In patient samples, GCN1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GCN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
